佰仁医疗(688198) - 2024 Q4 - 年度业绩

Financial Performance - The total operating revenue for 2024 reached RMB 502.83 million, representing a year-on-year increase of 35.67%[3] - The net profit attributable to the parent company was RMB 145.46 million, up 26.26% compared to the previous year[10] - The basic earnings per share increased to RMB 1.06, reflecting a growth of 24.71% year-on-year[10] - The net profit attributable to the parent company, excluding non-recurring gains and losses, was RMB 162.04 million, a 15.49% increase year-on-year[10] - The company effectively balanced short-term investments and long-term returns, achieving a net profit margin of 32.23% after excluding share-based payment impacts[10] Research and Development - Research and development expenses grew by 56.14%, accounting for 30.68% of total operating revenue[9] - The company launched three new products, including "vascular biological patches" and "transcatheter aortic valve systems," contributing to revenue growth[9] Asset Management - The total assets at the end of the reporting period were RMB 1,452.96 million, a 9.49% increase from the beginning of the period[10] - The weighted average return on equity rose to 11.97%, an increase of 1.91 percentage points[3] Segment Performance - The revenue from the cardiac valve replacement and repair segment grew by 64.42%, with artificial biological heart valve revenue increasing by 75.23%[8]